Pharmacogenomics Top Open Access Journals
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This relatively new field combines
pharmacology (the science of drugs) and
genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup.Many
drugs that are currently available are “one size fits all,” but they don't work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects (called
adverse drug reactions). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States. With the knowledge gained from the Human
Genome Project, researchers are learning how inherited differences in genes affect the body’s response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent
adverse drug reactions. Conditions that affect a person’s response to certain
drugs include clopidogrel resistance, warfarin sensitivity, warfarin resistance, malignant hyperthermia, Stevens-Johnson syndrome/toxic epidermal necrolysis, and thiopurine S-methyltransferase deficiency. The field of
pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future,
pharmacogenomics will allow the development of tailored
drugs to treat a wide range of
health problems, including
cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.
High Impact List of Articles
-
Outcome measures in amyotrophic lateral sclerosis clinical trials
Sabrina Paganoni, Merit Cudkowicz, James D Berry
Clinical Trail Methodology: Clinical Investigation
-
Outcome measures in amyotrophic lateral sclerosis clinical trials
Sabrina Paganoni, Merit Cudkowicz, James D Berry
Clinical Trail Methodology: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
11th International Congress on Targeted Anticancer Therapies
Valrerie Helin, Ohad Hammer, Jean-Pierre Armand
Conference Report: Clinical Investigation
-
11th International Congress on Targeted Anticancer Therapies
Valrerie Helin, Ohad Hammer, Jean-Pierre Armand
Conference Report: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
Relevant Topics in Clinical